Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Assets (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Assets for 4 consecutive years, with $343.3 million as the latest value for Q4 2025.

  • Quarterly Assets rose 114.09% to $343.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $343.3 million through Dec 2025, up 114.09% year-over-year, with the annual reading at $343.3 million for FY2025, 114.09% up from the prior year.
  • Assets hit $343.3 million in Q4 2025 for Taysha Gene Therapies, up from $316.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $343.3 million in Q4 2025 to a low of $81.5 million in Q2 2023.
  • Historically, Assets has averaged $182.7 million across 4 years, with a median of $163.2 million in 2022.
  • Biggest five-year swings in Assets: crashed 42.71% in 2023 and later surged 145.75% in 2024.
  • Year by year, Assets stood at $126.3 million in 2022, then skyrocketed by 36.79% to $172.7 million in 2023, then decreased by 7.16% to $160.4 million in 2024, then surged by 114.09% to $343.3 million in 2025.
  • Business Quant data shows Assets for TSHA at $343.3 million in Q4 2025, $316.6 million in Q3 2025, and $333.3 million in Q2 2025.